gms | German Medical Science

102. Jahrestagung der DOG

Deutsche Ophthalmologische Gesellschaft e. V.

23. bis 26.09.2004, Berlin

Best’s vitelliforme macular dystrophy: function of bestrophin and the light-peak in the EOG

Meeting Abstract

  • corresponding author O. Strauß - Experimentelle Ophhalmologie, Kopf- und Hautzentrum, Universitätsklinikum Hamburg-Eppendorf
  • R. Rosenthal - Institut für Klinische Physiologie, Campus Benjamin Franklin, Charite - Universitätsmedizin Berlin
  • C. Wadelius - Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University, Uppsala/S
  • B. Bakall - Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University, Uppsala/S
  • R. P. Gallemore - Retina-Vitreous Associates Medical Group, Jules Stein Eye Institute, UCLA School of Medicine, Los Angeles/USA
  • N. S. Peachey - Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland/USA
  • A. D. Marmorstein - Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland/USA

Evidenzbasierte Medizin - Anspruch und Wirklichkeit. 102. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft. Berlin, 23.-26.09.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04dogSO.05.15

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dog2004/04dog465.shtml

Veröffentlicht: 22. September 2004

© 2004 Strauß et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Best's vitelliforme macular dystrophy represents a rare autosomal dominant hereditary form of macular dystrophy. The main characteristics are an early onset of the disease and a reduction in the light-peak to dark ratio in the patient's EOG. Since the vitelliforme macular dystrophy share many similarities with age-related macular degeneration the understanding of the patho-mechanisms of Best's disease would improve the understanding of mechanisms leading to age-related macular degeneration. The cause for Best's macular dystrophy are mutations in the gene for bestrophin. 4 different homologues of bestrophin are known from which bestrophin 2-4 were found to be expressed in the CNS, colon and skeletal muscle. The function of the bestrophins is not fully understood.

Bestrophin-1 is a membrane protein exclusively expressed in the retinal pigment epithelium (RPE) where it is localised in the basolateral membrane. It physically interacts with the phosphatase PPA2. During the last 2 years betrophins 1 and 2 were described as members of a family of Ca2+-dependent Cl channels. This would explain the reduction in the light-peak because the light-peak is generated by activation of basolateral Cl conductance in the RPE. The reduction of the light-peak in the patients EOG would be explained by a loss of Cl channel function in all so far investigated mutant forms. However, there are other observations which challenge this hypothesis. First, with the knowledge of the bestrophin-1 gene, new mutations could be described from patients with macular dystrophy showing normal light-peaks. Furthermore, the Cl channel function of bestrophin in heterologeous expression systems could not be reproduced by all groups. In addition, bestrophin-1 was found to alter activity of voltage-gated Ca2+ channels by means of their time- and voltage-dependency. 2 investigated mutant bestrophins showed different effects on the time-dependent activation and inactivation of Ca2+-channels. Investigation of the light-peak in the rat EOG revealed a contribution of Ca2+-channels in the generation of the light-peak. Changes in the light-peak amplitude after transfection with wild-type or mutant bestrophin-1 were in accordance with observed changes in Ca2+-channel activity.

In summary, there are two alternative models of the bestrophin-1 function. Investigation of transgenic or bestrophin deficient mice would either combine these two models or lead to rejection of one of the two models. Due to the different expression patterns the study of the bestrophin function would improve the understanding of function other tissues.